Doctors should think twice before prescribing drug therapies when faced with someone battling depression, as exercise may be more effective, according to a new study.
Alto Neuroscience has said its therapeutic approach to depression of matching patients to drugs based on brain biomarkers has shown promise in a phase 2a trial.
Cybin has unveiled phase 2 results with its psychedelic medicine for major depressive disorder, which it says support moving the drug into a phase 3 programme.
People with depression can sometimes have impaired memory, particularly for positive events, which can contribute to cognitive problems and impair their daily lives.
Japanese pharma group Otsuka has signed an agreement to acquire Canada's Mindset Pharma, a specialist in psychedelic medicines for neuropsychiatric disorders.
Juli, an artificial intelligence-powered platform to help people manage chronic health conditions, has been shown to improve outcomes in a pair of randomised clinical tria
A report issued by the office of US Senator Bernie Sanders has claimed that the high prices being charged for new GLP-1 agonist-based obesity therapies like Novo Nordisk’s
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.